Zinbryta vs. Tecfidera

• Are Tecfidera and Zinbryta the Same Thing?
• What Are Possible Side Effects of Zinbryta?
• What Are Possible Side Effects of Tecfidera?
• What Is Zinbryta?
• What Is Tecfidera?
• What Drugs Interact with Zinbryta?
• What Drugs Interact with Tecfidera?
• How Should Zinbryta Be Taken?
• How Should Tecfidera Be Taken?

Zinbryta (daclizumab) injection and Tecfidera (dimethyl fumarate) are used to treat patients with relapsing forms of multiple sclerosis (MS).

Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Zinbryta and Tecfidera belong to different drug classes. Zinbryta is an interleukin-2 receptor blocking antibody and Tecfidera is a fumaric acid ester.

Side effects of Zinbryta and Tecfidera that are similar include skin rash.

Side effects of Zinbryta that are different from Tecfidera include runny or stuffy nose, upper respiratory tract infection, bronchitis, influenza, mouth pain, sore throat, eczema, swollen lymph nodes, depression, increased alanine aminotransferase (ALT), anemia, acne, and fever.

Side effects of Tecfidera that are different from Zinbryta include flushing, abdominal pain, diarrhea, nausea, vomiting, itching, redness, and indigestion.

Zinbryta may interact with drugs or herbal products that are toxic to the liver.

Tecfidera may interact with other drugs.

Common side effects of Zinbryta include:

• runny or stuffy nose
• upper respiratory tract infection
• rash, including drug rash
• influenza
• skin rash
• mouth pain
• sore throat
• bronchitis
• eczema
• swollen lymph nodes
• depression
• increased alanine aminotransferase (ALT)
• acne
• anemia, and
• fever

Less common side effects of Zinbryta include:

• abnormal liver function test,
• decreased lymphocyte count
• diarrhea
• dry skin
• skin redness
• hair bumps (folliculitis)
• increased liver enzymes
• laryngitis
• enlarged lymph nodes
• pneumonia
• itching
• psoriasis
• skin peeling
• toxic skin eruption, and
• viral infection

Common side effects of Tecfidera include:

• flushing,
• abdominal pain,
• diarrhea,
• nausea,
• vomiting,
• rash,
• itching,
• redness, and
• indigestion.

Zinbryta (daclizumab) injection is an interleukin-2 receptor blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Tecfidera (dimethyl fumarate) is a fumaric acid ester used to treat relapsing forms of multiple sclerosis (MS).

Zinbryta may interact with hepatotoxic drugs or herbal products. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant before taking Zinbryta. It is unknown if it would affect a fetus. It is unknown if Zinbryta passes into breast milk or if it would affect a nursing infant. Consult your doctor before breastfeeding.

Tecfidera may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to be become pregnant before using Tecfidera; it is unknown how it would affect a fetus. There is a pregnancy registry that monitors pregnancy outcomes in women exposed to Tecfidera during pregnancy and you may be encouraged to enroll. It is unknown if Tecfidera passes into breast milk. Consult your doctor before breastfeeding.

The recommended dosage of Zinbryta is 150 milligrams once monthly.

The starting dose of Tecfidera is 120 mg twice daily for seven days by mouth. After seven days, maintenance doses of Tecfidera are 240 mg taken twice daily by mouth.